mylan inc - health news
Mylan Inc. announced yesterday that it plans to launch a generic version of Copaxone, Teva Pharmaceutical Industries Ltd. intravenous treatment for multiple sclerosis, in the second half of 2013. Mylan added that patent litigation and US Food and Drug Administration (FDA) approval of its drug are pending. In addition, the firm announced yesterday that it has entered into a facility agreement with a syndicate of banks to securitize up to $300 million of U.S. accounts receivable. The facility is committed and has a maturity of three years. View and share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Agtech Firm Expands In Australia With Local Purchase
December 11, 2023

Israeli Drone Safety Firm In New Partnership To Boost UAV Safety
December 10, 2023

Weizmann Program Boosts Israeli-Canadian Brain Research
December 10, 2023

Israel And UAE Ink New Deal To Connect Ports Via Land Bridge
December 07, 2023
Facebook comments